Oncolytic Virus Therapy Pipeline Expands with 100+ Companies Developing Novel Cancer Treatments
Key Insights
The oncolytic virus therapy landscape has expanded steadily over the past decade, with over 100 companies worldwide pursuing clinical or preclinical programs developing 110+ oncolytic virus drugs.
Key market drivers include growing cancer incidence in hard-to-treat solid tumors, increasing understanding of cancer biology, advancements in viral engineering, and rising adoption of personalized medicine approaches.
Leading companies such as Candel Therapeutics, Oncolytics Biotech, and CG Oncology are advancing promising therapies like CAN-2409, Pelareorep, and CG0070 through Phase III clinical trials.
The oncolytic virus therapy landscape has experienced remarkable growth over the past decade, with over 100 companies worldwide now pursuing clinical or preclinical programs. According to DelveInsight's comprehensive analysis, this expanding field encompasses 110+ oncolytic virus drugs in various stages of development, representing a robust pipeline for innovative cancer treatments.
Market Drivers Fuel Therapeutic Innovation
Several key factors are driving the expansion of oncolytic virus therapy development. The global rise in cancer prevalence, particularly in hard-to-treat solid tumors, has intensified demand for novel, effective treatment modalities. Conventional therapies such as chemotherapy and radiation often have significant side effects and limited long-term efficacy, motivating the adoption of immunotherapeutic alternatives like oncolytic virus therapies.
Growing knowledge of cancer biology has enabled the development of oncolytic virus therapies that selectively target and destroy cancer cells while sparing healthy cells. Advancements in viral engineering are enabling more precise, targeted oncolytic virus therapies, significantly expanding the global market. Additionally, oncolytic virus therapies align closely with personalized treatment approaches by enabling tailored viral constructs and immunomodulatory payloads based on tumor genomics.
Leading Companies Drive Pipeline Progress
Key oncolytic virus companies such as Oncolytics Biotech, SillaJen, Candel Therapeutics, Binhui Biopharmaceutical (search), Oryx GmbH, Oncolys Biopharma, EpicentRx (search), Theriva Biologics, Lokon Pharma, DNAtrix, Surv BioPharma Inc., Treovir, Immvira Pharma, Virogin Biotech, OrienGene Biotechnology, Apices Soluciones, Vyriad, Transgene, BioEclipse Therapeutics, Imugene (search), CG Oncology, Istari Oncology (search), Akamis Bio, and Elicera Therapeutics (search) are evaluating new oncolytic virus drugs to improve the treatment landscape.
A few leaders, such as Candel Therapeutics, Binhui Biopharmaceutical (search), Oncolytics Biotech, EpicentRx (search), and Hangzhou Converd (search), anchor the mid and late-stage pipeline with promising therapeutic candidates.
Advanced Clinical Programs Show Promise
Several oncolytic virus therapies have progressed to Phase III clinical trials, demonstrating the maturity of this therapeutic approach. CAN-2409 from Candel Therapeutics is being evaluated for prostate cancer through intratumoral administration. Pelareorep from Oncolytics Biotech is advancing in Phase III trials for advanced pancreatic cancer via intravenous delivery. CG0070 from CG Oncology is progressing through Phase III development for bladder cancer using intravesical administration.
Mid-stage developments include AdAPT-001 from EpicentRx (search) in Phase II trials for sarcoma and refractory solid tumors, and PVS-RIPO from Istari Oncology (search) in Phase II for glioblastoma and malignant melanoma. Early-stage programs feature VAXINIA (CF33-hNIS) from Imugene (search) in Phase I trials for solid tumors and NG-350A from Akamis Bio in Phase I development for rectal cancer.
Established Therapies Validate Approach
Two approved oncolytic virus therapies have already validated the therapeutic concept. IMLYGIC (talimogene laherparepvec), developed by Amgen, represents a first-of-its-kind oncolytic viral therapy for melanoma that cannot be surgically removed. In the Phase III OPTiM trial, IMLYGIC produced durable responses in about 16% of patients, compared with 2% with GM-CSF alone, and overall responses in roughly 26%. Although its independent effect on survival and deep organ metastases is modest, its value is most evident when combined with checkpoint inhibitors, with early data showing response rates approaching 56%.
Oncorine, also known as H101, developed by Shanghai Sunway Biotech (search) in China, became the first oncolytic virus approved for cancer treatment by the Chinese State Food and Drug Administration (CFDA) in November 2005. Since its introduction, it has demonstrated a favorable safety profile and notable antitumor activity across various cancers and malignant pleural effusions.
Recent Developments Signal Innovation
Recent developments highlight the field's continued evolution and innovation. In November 2025, Imugene (search) Ltd and JW Therapeutics (search) announced a co-development collaboration to evaluate the combination of Imugene's oncolytic virus CF33-CD19 (onCARlytics) and JW's Carteyva®, a CD19 (search)-directed autologous CAR-T cell therapy, for patients with advanced solid tumors. The approach utilizes Imugene's CF33-CD19 virus to induce CD19 expression on tumor cells, rendering them susceptible to targeting by CD19 CAR-T therapies, representing a transformative "mark and kill" strategy.
In July 2025, Calidi Biotherapeutics (search) received Fast Track designation from the U.S. Food and Drug Administration (FDA) for CLD-201 (SuperNova), the company's allogeneic adipose stem-cell loaded oncolytic virus for the treatment of soft tissue sarcoma.
Regulatory recognition has been significant, with Candel Therapeutics announcing in May 2025 that the FDA had granted Regenerative Medicine Advanced Therapy (RMAT) designation to CAN-2409 (aglatimagene besadenovec) for the treatment of newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease. CAN-2409 was also previously granted FDA Fast Track designation for the same indication.
Therapeutic Mechanisms and Applications
Oncolytic virus therapy represents an innovative form of cancer treatment that uses genetically engineered or naturally occurring viruses to selectively infect and destroy cancer cells. These viruses replicate inside tumor cells, causing them to burst while leaving healthy cells largely unharmed. As the cancer cells break apart, they release tumor antigens that help activate the body's immune system, enhancing its ability to recognize and attack remaining cancer cells.
This dual action of direct tumor destruction and immune stimulation makes oncolytic virus therapy a promising approach in modern oncology, often used alongside other treatments such as immunotherapy or chemotherapy. Oncolytic virus cancer therapies can be used for both diagnosis and treatment of cancer, can function as cancer vaccines by boosting tumor-specific T-cell responses, and can be engineered with immunostimulatory molecules to enhance immune activation. They show strong synergy when combined with other immunotherapies, such as checkpoint inhibitors.
Combination Strategies Address Delivery Challenges
The field recognizes that systemically administered oncolytic viruses have shown limited therapeutic benefit in several clinical trials, and delivering them effectively to metastatic sites remains a major challenge. Therefore, using chemotherapy as a systemic adjuvant to localized oncolytic virus therapy is of significant clinical interest and is currently being actively investigated.
Because chemotherapy is systemic, it is often combined with oncolytic viruses, which typically require localized delivery to achieve a strong antitumor effect. This combination approach leverages the systemic nature of chemotherapy with the targeted tumor destruction capabilities of oncolytic viruses.